Clinical trials: Severe Asthma
Asthma
Risk Factors for Early Remodelling in Severe Asthma in Children
Background: Asthma is a frequent disease characterized by bronchial hyperresponsiveness, inflammation and remodeling. Consistent epidemiological data indicate that outcome of asthma in adults may be determined in early childhood.
- Trial name
- P'tit-ASTHME (NCT02806466)
- Testing
- Fiberoptic bronchoscopy
- Where
- 2 sites in France
- Volunteers
- 67 people
- Sponsor
- University Hospital, Bordeaux
Moderate to Severe Persistent Bronchial Asthma
Controller Medications in the Management of Bronchial Asthma
The purpose of this study is to know the effect of another controller medication add on to the inhaled corticosteroid and long acting β2 agonist on clinical symptom, lung function and compliance in patients of moderate to severe…
- Trial name
- NCT01055041
- Testing
- inhaled budesonide and formeterol plus oral montelukast, inhaled budesonide and formeterol plus oral doxophylline, Doubling the dose of inhaled budesonide and formeterol
- Where
- India
- Volunteers
- 50 people
- Sponsor
- Government Medical College, Bhavnagar
Asthma
A Safety and Efficacy Study of Mepolizumab in Subjects With Severe Asthma
Mepolizumab, a humanized monoclonal antibody, has been developed as an add-on treatment for subjects with severe asthma with eosinophilic inflammation.
- Trial name
- NCT03562195
- Testing
- Mepolizumab 100 milligrams, Salbutamol
- Where
- 42 sites in China
- Volunteers
- 300 people
- Sponsor
- GlaxoSmithKline
Asthma, Acute Asthma
Effect of Addition of Single Dose of Oral Montelukast to Standard Treatment in Acute Asthma in Preschool Children.
The purpose of this study is to determine if adding single dose of oral montelukast to the standard treatment of systemic glucocorticoids plus short acting beta-2 agonist for treatment of acute wheezing provide additional…
- Trial name
- NCT01304901
- Testing
- montelukast 4 mg granule
- Where
- Turkey (Türkiye)
- Volunteers
- 80 people
- Sponsor
- Kecioren Education and Training Hospital
Asthma
Measuring the Effect of Dupilumab Treatment on Mucociliary Clearance (MCC) in Subjects With Moderate to Severe Asthma
Single center, randomized, placebo- controlled study to assess change in mucociliary clearance of moderate to severe asthma patients after treatment with dupilumab or placebo.
- Trial name
- NCT04743791
- Testing
- Dupilumab
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Sally E. Wenzel MD
Asthma
Evaluation of SAR440340 and as Combination Therapy With Dupilumab in Moderate-to-Severe Asthma Participants
Primary Objective: To evaluate the effects of SAR440340 with or without dupilumab, compared to placebo, on reducing the incidence of "loss of asthma control" (LOAC) events.
- Trial name
- NCT03387852
- Testing
- SAR440340, Dupilumab, Fluticasone or Fluticasone/salmeterol combination
- Where
- 71 sites in United States, Argentina and 6 more
- Volunteers
- 296 people
- Sponsor
- Sanofi
Allergic Rhinitis Due to House Dust Mite, Allergic Asthma
Evaluate Measurement Instruments Relevance in Assessing Effectiveness of ACARIZAX® in House Dust Mite Allergic Rhinitis
The study is a single-center, observational design with a 12-month duration. Approximately 100 Chinese adult (18-65 years old) and adolescent (12-17 years old) with moderate to severe house dust mite (HDM) allergic rhinitis (AR)…
- Trial name
- NCT06151938
- Testing
- Standardised allergen extract from house dust mites
- Where
- China
- Volunteers
- 100 people
- Sponsor
- ALK-Abelló A/S
Asthma
A Study of Lebrikizumab (RO5490255) in Participants With Severe Oral Corticosteroids (OCS) Dependent Asthma
This randomized, multicenter, double-blind, placebo-controlled, parallel-group study will evaluate the efficacy of lebrikizumab compared with placebo, as measured by the ability of participants to achieve lower daily doses of…
- Trial name
- NCT01987492
- Testing
- Lebrikizumab
- Where
- 71 sites in United States, Australia and 14 more
- Volunteers
- 230 people
- Sponsor
- Hoffmann-La Roche
Asthma
Efficacy of Ciclesonide and Fluticasone Propionate in Adult Patients With Moderate and Severe Persistent Asthma (18 to 75 y) (BY9010/IT-101)
The aim of the study is to compare the safety and efficacy of ciclesonide versus fluticasone propionate on the lung function, symptoms, use of rescue medication, and occurrence of side effects (such as candidiasis, hoarseness) in…
- Trial name
- NCT00163319
- Testing
- Ciclesonide
- Where
- 89 sites in Belgium, France and 5 more
- Volunteers
- 500 people
- Sponsor
- AstraZeneca
Asthma, Chronic Obstructive Pulmonary Disease
Trial Comparing Effect of He/O2 to Medical Air on Pulmonary Function Disease
This clinical trial will include healthy volunteers, COPD patients and asthmatic patients who will breathe He/O2 78:22, He/O2 65:35 and medical air consecutively in a randomised order.
- Conditions
- Asthma, Chronic Obstructive Pulmonary Disease, Healthy
- Trial name
- NCT00801307
- Testing
- spirometer
- Where
- Germany
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Air Liquide SA
Asthma
Efficacy of Dupilumab Added to Medium Dose Inhaled Corticosteroid/Long-acting Beta-agonist (ICS/LABA) in Comparison to ICS Dose Escalation to High Dose ICS/LABA in Adolescent and Adult Patients With Uncontrolled Asthma
This study is researching a drug called dupilumab. The study is focused on patients who have uncontrolled asthma. Asthma is a condition where the airways narrow and swell, making it difficult to breathe.
- Trial name
- AIM4:Next Step (NCT06572228)
- Testing
- dupilumab, ICS/LABA
- Where
- 77 sites in United States, Canada and 4 more
- Volunteers
- 120 people
- Sponsor
- Regeneron Pharmaceuticals
Asthma
Withania Somnifera for Moderate-to-Severe Persistent Asthma
This randomized, double-blind, placebo-controlled study evaluated Withania somnifera root powder as a complementary therapy in adults with moderate-to-severe persistent asthma receiving standard asthma treatment.
- Trial name
- WISTA (NCT07787507)
- Testing
- Withania somnifera Root Powder, Standard Asthma Treatment
- Where
- India
- Volunteers
- 120 people
- Sponsor
- Aligarh Muslim University
Asthma
A Phase 3a, Repeat Dose, Open-label, Long-term Safety Study of Mepolizumab in Asthmatic Subjects
This is a multi-center, open-label, long-term study of subcutaneously (SC) administered mepolizumab 100mg in addition to standard of care (SOC), in subjects with severe eosinophilic asthma.
- Trial name
- NCT02135692
- Testing
- Mepolizumab, SOC
- Where
- 114 sites in United States, Argentina and 16 more
- Volunteers
- 339 people
- Sponsor
- GlaxoSmithKline
Asthma
Effect of Omalizumab on Expression of IgE Receptors in Adults With Severe, Inadequately Controlled Allergic Asthma
The aim of this study is to evaluate the expression of IgE high affinity receptors (the part of the cell associated with allergic response) in patients suffering from uncontrolled severe asthma despite long term treatment with…
- Trial name
- NCT00454051
- Testing
- Omalizumab
- Where
- France
- Volunteers
- 31 people
- Sponsor
- Novartis Pharmaceuticals
Pediatric Asthma, Acute Asthma
Bilevel Positive Airway Pressure (BPAP) for Severe Asthma
The goal of this clinical trial is to assess the feasibility of early initiation of bilevel positive airway pressure (BPAP) in the emergency department (ED) for children with severe asthma exacerbations.
- Conditions
- Pediatric Asthma, Acute Asthma, BiPAP, Non-invasive Positive Pressure Ventilation
- Trial name
- NCT07582211
- Testing
- Bilevel positive airway pressure ventilation
- Where
- 3 sites in United States
- Volunteers
- 36 people
- Sponsor
- Columbia University
Severe IgE-mediated Asthma
Study to Assess the Efficacy and Safety of Omalizumab Treatment on ICS Reduction for Severe IgE-mediated Asthma
Assess efficacy and safety of omalizumab treatment during 12 months in order to reduce the use of inhaled corticosteroid (ICS) in pediatric and adult participants with severe Immunoglobulin E (IgE)-mediated asthma inadequately…
- Trial name
- MEXIC (NCT01912872)
- Testing
- Omalizumab, Budesonide, Formoterol
- Where
- 21 sites in Mexico
- Volunteers
- 112 people
- Sponsor
- Novartis Pharmaceuticals
Asthma
Phosphodiesterase 4 Inhibitor, Roflumilast, and the Effects of Inhibition in Severe Asthma
This study evaluates the effects of roflumilast on restoring response β2 adrenoreceptor agonists in low T2, obese asthmatics. One group of participants will receive roflumilast for 3 months, while the other will receive a placebo.
- Trial name
- NCT04108377
- Testing
- Roflumilast
- Where
- United States
- Volunteers
- 5 people, healthy volunteers welcome
- Sponsor
- University of California, Davis
Asthma
Efficacy and Safety of Omalizumab in Children (6 - < 12 Years) With Moderate-severe, Inadequately Controlled Allergic Asthma
A substance called immunoglobulin E (IgE), which is naturally produced by our body, has a key role in generating asthma attacks.
- Trial name
- NCT00079937
- Testing
- Omalizumab, Fluticasone
- Where
- 56 sites in United States
- Volunteers
- 628 people
- Sponsor
- Novartis Pharmaceuticals
Asthma
AKITA Inhaled Steroid Suspension for Inhalation (AICS) in Subjects With Asthma
The goal of treatment with AICS is weaning from oral corticosteroids, i.e. a reduction of the oral corticosteroid dose. An anticipated treatment benefit of AICS is a reduction of oral corticosteroid dose and stability/improvement…
- Trial name
- NCT01200108
- Testing
- Budesonide
- Where
- 24 sites in Germany, Poland and 1 more
- Sponsor
- Activaero GmbH
Severe Persistent Asthma
Bronchial Thermoplasty: Effect on Neuronal and Chemosensitive Component of the Bronchial Mucosa
In severe bronchial asthma the mechanism of inflammation and bronchospasm is complex and still not clarified. The smooth muscle cells play an important role from the mechanical point of view, as a culmination of neurogenic…
- Trial name
- BT-ASMN (NCT01839591)
- Testing
- catheter ALAIR
- Where
- Italy
- Volunteers
- 12 people
- Sponsor
- Azienda USL Reggio Emilia - IRCCS